Company Overview

Modular Medical, Inc. is a U.S.-based medical device company focused on the design and development of insulin delivery technologies for people with diabetes. The company operates within the medical technology and diabetes care industries, with its primary emphasis on creating simplified, user-friendly insulin pump systems intended to expand access to pump therapy for broader patient populations, including individuals with Type 1 and Type 2 diabetes who may not currently use traditional insulin pumps. Its principal product platform is the modular insulin patch pump system designed to provide continuous subcutaneous insulin infusion with reduced complexity and lower expected cost compared with conventional durable pump systems.

The company traces its origins to technology and intellectual property associated with diabetes device innovator and insulin pump pioneer Dean Kamen. Modular Medical evolved around the commercialization of a simplified insulin delivery architecture intended to improve usability and affordability in diabetes management. Public filings and investor materials describe the company’s strategy as centered on scalable disposable and reusable pump components, ease of training, and expanded accessibility for patients and healthcare providers. Data regarding large-scale commercial adoption remains limited because the company is still in the development and pre-commercialization stage based on available public sources.

Business Operations

Modular Medical primarily operates through a single business focused on diabetes-related medical devices and insulin delivery systems. The company’s revenue generation strategy is expected to rely on sales of its insulin pump platform, including reusable controller components and disposable insulin delivery modules, although historical revenues have been limited while the company advances development, regulatory, and commercialization activities. Its operations are concentrated in the United States, where it conducts product development, regulatory planning, engineering, clinical-related activities, and corporate administration.

The company’s principal assets include proprietary insulin pump technology, related intellectual property, and engineering capabilities associated with wearable insulin delivery systems. Public disclosures indicate that Modular Medical has pursued manufacturing and development relationships to support future commercialization efforts, though major global joint ventures or large-scale operating subsidiaries have not been prominently disclosed in public filings. The company’s operational strategy emphasizes simplified training requirements, lower-cost device architecture, and broader market accessibility relative to traditional insulin pump providers.

Strategic Position & Investments

Modular Medical’s strategic direction centers on expanding insulin pump adoption among patients who may find conventional systems too expensive or operationally complex. The company has positioned its technology as a more streamlined alternative within the insulin delivery market, targeting both intensive insulin users and patients transitioning from multiple daily injection therapies. Strategic initiatives have included product development, regulatory pathway advancement, clinical evaluation activities, and preparation for commercialization infrastructure.

The company’s investment focus has largely been directed toward research and development, intellectual property expansion, and manufacturing readiness. Public disclosures reference technology originating from diabetes device innovations associated with Dean Kamen and related engineering development efforts. Modular Medical operates in a competitive sector that includes larger diabetes technology companies, but its positioning is differentiated by an emphasis on simplicity, modularity, and potentially lower overall therapy costs. Information regarding significant acquisitions, diversified portfolio holdings, or extensive subsidiary networks is limited in available public records.

Geographic Footprint

Modular Medical is headquartered in the United States, with corporate operations historically centered in California. Its primary operational and commercial focus remains the U.S. diabetes care market, particularly in connection with regulatory development and anticipated product commercialization activities. Based on publicly available filings, the company does not currently maintain a broad multinational operating footprint comparable to larger global medical device manufacturers.

Although the company’s direct international commercial presence appears limited, the diabetes technology market it targets is global in scope, including potential future opportunities across North America, Europe, and other regions with growing diabetes prevalence. Publicly available information does not indicate substantial international manufacturing facilities, foreign operating subsidiaries, or major overseas investments at this stage.

Leadership & Governance

Modular Medical’s leadership team includes executives and directors with backgrounds in medical devices, diabetes technology, engineering, and healthcare innovation. The company’s governance approach, as reflected in public filings, emphasizes advancing regulatory readiness, product commercialization, and long-term shareholder value through focused development of its insulin delivery platform. The company’s strategic vision has consistently centered on simplifying insulin pump therapy to expand adoption among underserved diabetes patient populations.

Key executives and leadership figures include:

• Jeb Besser – Chief Executive Officer
• Mark Massaro – Chief Financial Officer
• Dean Kamen – Founder and technology innovator associated with the company’s insulin pump platform
• Paul DiPerna – Chairman of the Board

Public disclosures indicate that leadership strategy prioritizes product accessibility, simplified patient experience, scalable manufacturing readiness, and progression toward broader commercialization within the diabetes technology sector.